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The c-family cytokine IL-2 activates signaling events that
contribute to cell survival and proliferation, the best-studied of
which are the STAT-5 and phosphatidylinositol 3-kinase (PI3K)
pathways. The starting point of this study was to define genes
regulated by the IL-2R-mediated PI3K pathway in T cells.
Accordingly, we used an erythropoietin (EPO) receptor chi-
meric receptor system in which IL-2-dependent HT-2 T cells
expressed a mutant EPO-IL-2R construct where Tyr-338 is
mutated to Phe. Cells expressing this mutant IL-2R chain fail
to induce phosphorylation of PI3K-p85/ or activate Akt, but
mediate normal IL-2-dependent proliferation and activation of
JAK1 and STAT-5A/B. Microarray analyses revealed differen-
tial regulation of numerous genes compared with cells express-
ing a wild-type IL-2R, including up-regulation of the IL-17
receptor subunit IL-17RA. Blockade of the PI3K pathway but
not p70S6K led toup-regulationof IL-17RA, andconstitutiveAkt
activation was associated with suppressed IL-17RA expression.
Moreover, similar to the mutant EPO-IL-2R chimera, IL-15
and IL-21 induced IL-17RA preferentially compared with IL-2,
and IL-2 but not IL-15 or IL-21 mediated prolonged activation
of the PI3K p85 regulatory subunit. Thus, there are intrinsic
signaling differences between IL-2 and IL-15 that can be attrib-
uted to differences in activation of the PI3K pathway.
Cytokine receptors exhibit remarkable redundancy in their
signaling cascades, in part because of widespread sharing of
receptor subunits (1). However, individual cytokines are gener-
ally found to have unique, non-redundant activities in vivo,
despite considerable overlap in signaling cascades. A striking
case in point is interleukin (IL)2-2 and IL-15, members of the
“c-superfamily” of cytokines. IL-2 and IL-15 use identical
receptor subunits, IL-2R and the common  (c) chain, to
mediate downstream signals. Both receptor complexes also
contain unique affinity-modulating subunits, IL-2R and
IL-15R, which mediate high affinity ligand binding. However,
the “private”  subunits have very short cytoplasmic domains
and are generally not thought to contribute directly to signal
transduction (reviewed in Refs. 2, 3). Despite sharing signaling
subunits, IL-2 and IL-15 mediate distinct events in vivo. Differ-
ential expression of their respective private subunits causes NK
cells and CD8 memory cells to be more sensitive to IL-15,
whereas newly activated CD4 T cells and Treg cells express
high levels of CD25/IL-2R and thus are regulated by IL-2.
Moreover, IL-2 and IL-15 exert opposing effects on survival and
expansion of the T cell memory population (3).
Because they share IL-2R and c, IL-2 and IL-15 have long
been presumed to trigger the same signaling pathways in target
cells, which may then be interpreted differently depending on
cell type. IL-2 and IL-15 activate the Janus (JAK) kinases-1 and
-3 leading to activation of the STAT-5 transcription factor
(3–7), and also the MAPK and phosphatidylinositol 3-kinase
(PI3K) pathways (8–10), leading to cell growth and inhibition
of apoptosis (reviewed in Refs. 11, 12). STAT-5 can be recruited
to any one of three distinct tyrosine residues on the IL-2R
chain (9, 13), whereupon it activates a variety of genes, partic-
ularly IL-2R (14) (Fig. 1A). This event leads to formation of a
high affinity IL-2 receptor and preferential expansion of anti-
gen-specific naı¨ve T cells. The PI3K pathway is activated via the
Shc adaptor binding to a single tyrosinewithin IL-12R, leading to
recruitment and phosphorylation of the regulatory subunits of
PI3K, p85/ (15). Activation of PI3K leads to phosphorylation of
the membrane lipid PIP2 converting it to PIP3, and subsequent
recruitment of pleckstrin homology (PH) domain-containing
kinases such as PDK1 and Akt/PKB. Akt in turn phosphorylates a
numberofdownstreamtargets that cumulatively serve topromote
cell survival, including GSK3/, FOXO proteins, and Bad
(reviewed inRef. 16).ThePI3Kpathway is alsoupstreamofmTOR
and p70 S6 kinase (p70S6K), rapamycin-sensitive signaling mole-
cules that contribute to IL-2-mediatedgrowth signaling (8, 16, 17).
Therefore, the JAK-STAT-5 and PI3K pathways mediate distinct
signaling events, and are critical components of the IL-2 and IL-15
signaling pathways.
IL-2 is produced primarily by newly activated CD4 T cells,
although CD8T cells and B cells are also sources of IL-2 (11).
Recently, a paradigm shift in how T cells produce cytokines
occurred with the discovery of a new subset of CD4 T helper
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(Th) cells distinct from Th1 and Th2, termed Th17. Differenti-
ation and expansion of these cells is driven by TGF, IL-6, and
IL-23. As the name implies, these cells produce IL-17 as well as
other pro-inflammatory cytokines including IL-17F and IL-22.
Interestingly, Th17 cells differentiate in opposition to Treg
cells, in part because development of Th17 cells requires TGF
and IL-6, whereas TGF without IL-6 promotes Treg develop-
ment (reviewed inRefs. 18, 19). It is becoming increasingly clear
that the Th17 population plays a major role in driving autoim-
munity, and efforts to block IL-17 or its receptor are under
serious consideration for anti-cytokine therapy (20, 21). Inter-
estingly, many c cytokines regulate the IL-17/IL-17 receptor
system. For example, IL-4 derived fromTh2 cells inhibits Th17
development (22), and IL-2 activation of STAT-5 appears to
inhibit Th17 differentiation in favor of Treg expansion,
although this is still somewhat controversial (23, 24). Con-
versely, IL-21 up-regulates the IL-17 receptor (25), and was
recently shown to be a mediator of Th17 differentiation (26–
28). IL-15 augments IL-17 expression, and both IL-15 and IL-17
are elevated in RA patients (29). However, the connections
between c cytokines and the IL-17 family remain poorly
understood.
IL-17 binds to a specific receptor on target cells composed of
IL-17RA and IL-17RC, and IL-17 activates a pro-inflammatory
signaling cascade leading to expression of chemokines, cyto-
kines and other inflammatory effector molecules (30, 31).
Although the IL-17 receptor is ubiquitously expressed, its func-
tion has mainly been evaluated on non-immune cells, particu-
larly epithelial cells and fibroblasts. The role of IL-17 in lym-
phocytes is unknown, and almost nothing is known about how
the IL-17 receptor is regulated.
The initial goalof thepresent studywas todefine specificmolec-
ular events mediated by the IL-2R-mediated PI3K pathway in T
cells.Microarray analyses revealed that activationof amutant IL-2
receptor that cannot activate PI3K leads to the up-regulation of
numerous immune genes, including IL-17RA. Moreover, IL-15
and IL-21 induce IL-17RApreferentially comparedwith IL-2, and
IL-17RA expression is limited by the PI3K pathway. Consistent
with this finding, IL-2butnot IL-15mediatesprolongedactivation
of the PI3K p85 regulatory subunit. Further studies revealed that
signaling by PI3K through Akt but not p70S6K leads to up-regula-
tion of IL-17RA. Thus, there are intrinsic signaling differences
between IL-2 and IL-15 that can be attributed to differences in
molecular activation of the PI3K pathway.
EXPERIMENTAL PROCEDURES
Cell Culture, Cell Lines, and Cytokine Stimulations—HT-2,
Jurkat, A20, and primary cells were maintained in RPMI 1640,
10% fetal bovine serum (Gemini Bioproducts, Woodland, CA),
2 mM glutamine, 0.05 mM 2--mercaptoethanol, penicillin/
streptomycin, and 1 nM recombinant human IL-2 (provided
by the Chiron Corporation, Emeryville, CA). HT-2.EPO,
HT-2.EPO5Y/, and HT-2.EPO1Y/ cells were maintained
in this medium with human EPO (a kind gift of Amgen, Thou-
sand Oaks, CA) in place of IL-2. ST2 cells were maintained in
-MEMwith 10% fetal bovine serumand antibiotics.HT-2 cells
were transfected by electroporation (32). For stimulations,
HT-2 cells were starved in phosphate-buffered saline, stripped
with 10 mM sodium citrate/140 nM NaCl, and incubated in
RPMI 1640/1% bovine serum albumin (Sigma) for 2–4 h. Stim-
ulations used IL-2 (5 nM), IL-15 (50 nM), IL-21 (50 nM), IL-17
(100 ng/ml), TNF (2 ng/ml), or EPO (50 units/ml) unless oth-
erwise indicated. Other cytokines were from R&D Systems
(Minneapolis, MN) or Peprotech (Rocky Hill, NJ). Primary
CD8Tcells were obtained frommouse spleenwith aCD8T
Cell Isolation kit (Miltenyi Biotech, Auburn, CA). All animal
protocols were approved by the University at Buffalo IACUC.
Microarray Analysis—To generate expression summary val-
ues fromAffymetrix GeneChips,MAS5.0 software in the “Affy”
package of Bioconductor in the R statistical computing envi-
ronment was used with its default settings, followed by global
normalization to bring the median expression values of all four
GeneChips to the same scale. This was done by selecting a base-
line GeneChip from the dataset and scaling each GeneChip to





For data quality control,MAS5.0 “present calls” was used to
filter out probe sets whose expression intensities were close to
background noise across the majority of samples before per-
forming differential gene analysis. Filtering of 2 “present calls”
was applied to either the EPO5Y/or EPO group,which led
to 47% data reduction for the comparisons. Further filtering
was performed to reduce variance between replicates of the
same condition by first ranking those selected probe sets based
on their intensity for each of the 4 GeneChips, followed by
filtering out those probe sets with 10% rank order differences
for replicatedGeneChips in the same group. This led to another
1% data reduction. Regularized Student’s t test was employed
to detect gene expression values significantly different between
groups. For multiple test correction, the false discovery rate
(FDR)was estimated using SAM, andwas 0 for all data sets (33).
Plasmids—EPO-IL-2R chimeras are described in Ref. 7. The
Myr-Akt construct was a kind gift of P. Tsichlis (34) and sub-
cloned into the pIRES2-EGFP plasmid (Invitrogen).
Proliferation Assays—[3H[Thymidine incorporation assays
were performed as described (32). 5  103 cells were washed
twice in phosphate-buffered saline and incubated with cyto-
kines for 24–48 h in triplicate. 5 h prior to harvesting, 1 Ci/
well of [3H]thymidine (PerkinElmer Life Science Products) was
added. Cells were harvested on a Skatron microwell harvester
and analyzed on a Wallac Microbeta counter (PerkinElmer).
Real-time RT-PCR, Immunoprecipitations, Western Blotting,
and EMSA—Total mRNAwas prepared with RNeasy kits (Qia-
gen). Real time RT-PCR was performed with SYBR-Green as
described (35). IL-17RA primers were from SuperArray (Fred-
erick, MD) (35). Immunoprecipitations were performed as
described (32) with -JAK1 (Santa Cruz Biotechnology), -p85
(Upstate Biotechnologies, Saranac, NY), and protein A- or pro-
tein G-agarose (Roche Applied Sciences). Western blots were
probed with 4G10, -p85 (Upstate Biotechnologies), -SHIP
(Santa Cruz Biotechnology), -PTEN (Cell Signaling, Beverly,
MA) or-JAK1. EMSAwere performed as described (7)with 10
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g of nuclear extract and 105 cpmof 32P-labeled probe per lane.
STAT-5A/B Abs were a kind gift from L. Hennighausen (9).
Flow Cytometry and ELISA—Apoptosis assays were per-
formed by staining with propidium iodide (PI) and GFP-An-
nexin V (32). Cells were analyzed on a FACS Calibur using
Cellquest software (Becton Dickinson, San Jose, CA). IL-17RA
staining was performed with rat anti-mouse IL-17RA M751
mAbs (kindly provided by Amgen, Seattle WA) as described
(36). ELISA assays were performed with commercial kits from
R&D and eBiosciences (San Diego, CA).
RESULTS
Genes Regulated by the IL-2-induced PI3K Pathway—IL-2
induces multiple signaling events in T cells, the best studied of
which are the JAK1/3-STAT-5 and PI3K pathways (37). While
many of the downstream targets of these pathways have been
defined, these pathways also exert overlapping functions in terms
of cellular survival andgrowthsignaling (11).Therefore,we sought
to delineate STAT-5-independent functions for the IL-2-induced
PI3K pathway in T cells. All known IL-2-dependent signaling
events proceed from tyrosine residues located within the IL-2R
andc subunits (11, 32).Wehave extensively examined themech-
anisms bywhich the IL-2R complex initiates these pathways using
a chimeric receptor system, in which the extracellular domains of
IL-2R and c have been replaced with the erythropoietin (EPO)
receptor and expressed stably in IL-2-dependent HT-2 T cells. In
this system, treating cells with EPO faithfully recapitulates IL-2-
dependent signaling (7, 9, 38). Former studies demonstrated that
activationofSTAT-5occurs independently through threeTyr res-
idues within IL-2R (Tyr-338, Tyr-392, and Tyr-510, also termed
FIGURE 1.Differential gene expressionmediated by the PI3K pathway through IL-2RY338. A, schematic diagram of the EPOR-IL-2R chimeric receptor
construct. The location of JAK-binding site (Box1/Box2) and the pathways activated by individual tyrosine residues are indicated. B, p85 subunit of PI3K is
activated through Tyr-338 (1Y). HT-2 cells expressing the indicated EPO-IL-2R chimeras were stimulated for 1 hwith EPO or IL-2. Lysates were immunoprecipi-
tated with -p85/ Abs, separated by SDS-PAGE, and immunoblotted with -Ptyr (4G10) Abs (top) or p85/ Abs (bottom). C, differentially expressed genes
in HT-2.EPO cells versus HT-2.EPO5Y/ cells. Gene differences with a p value 0.01 are shown (222 total genes). D, selected genes enhanced in
HT-2.EPO5Y/ cells or HT-2.EPO cells. E, IL-17RA surface expression is elevated in HT-2.EPO5Y/ cells. The indicated cell lines were incubated in EPO for
24 h and IL-17RA expression was assessed by flow cytometry. Filled histograms, isotype control.
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“1Y,” “5Y,” and “6Y,” Fig. 1A) (9, 13). However, activation of PI3K
occurs only through Tyr-338 (1Y) via the Shc adaptor protein
(Fig. 1B and Ref. 39). Importantly, these chimeric receptors
demonstrated that the PI3K pathway is not required for prolif-
erative signaling, as HT-2.EPO5Y/ or HT-2.EPO6Y/ cells
can bemaintained indefinitely in EPO and show similar growth
kinetics to a wild-type receptor (9). To define genes regulated
by the PI3K pathway that are not required for proliferation, we
compared gene expression in HT-2 cells expressing the EPO
(wild-type) chimera to the EPO5Y/ chimera and cultured in
EPO, using replicate AffymetrixMouse Expression Array 430A
GeneChips. There was a high replicate correlation between
chips (r  0.98, data not shown). 883 genes were differentially
regulated with p values0.05 (data not shown), and 222 genes
were differentially regulated with p values0.01 (Fig. 1, C and
D and supplemental Tables S1 and S2). As expected, many
genes were up-regulated in HT-2.EPO cells compared with
HT-2.EPO5Y/ cells, indicating that these are direct or indi-
rect targets of the PI3K pathway. The most strongly enhanced
of these genes (100-fold) was that encoding the E1A enhanc-
er-binding protein (E1AF), an ets oncogene transcription factor
involved in Ewings sarcoma (supplemental Table S1) (40). In
addition, many genes were up-regulated in HT-2.EPO5Y/
cells, suggesting that signals mediated by IL-2RY338 inhibit
expression of certain genes. The strongest of these (32-fold)was
the pregnancy-specific glycoprotein 17 (supplemental Table
S2), which is thought to play an immunoregulatory role during
pregnancy (41). Interestingly, genes involved in known IL-2-
mediated signaling pathways were differentially regulated,
including STAT-5A, Bcl-x, and FK506-binding proteins. In
addition, T cell receptor (TCR)-associated signaling genes were
differentially regulated, includingTCR, Lck-interacting trans-
membrane protein 1 (LIME-1), PKC, Bcl-10, and Cot-2 (Fig.
1D) (42, 43).
Of particular interest to us was the enhancement of the gene
encoding IL-17RA, the receptor for IL-17, in HT-2.EPO5Y/
cells (Fig. 1D). Although IL-17RA is expressed ubiquitously
(30), its surface expression varies widely (36), and nothing is
known about mechanisms of IL-17RA gene regulation. By flow
cytometry, HT-2 cells express quite high baseline levels of
IL-17RA when cultured in IL-2 (Fig. 1E). Normal CD8 and
CD4 T cells also express IL-17RA (data not shown, Ref. 25).
HT-2.EPO and HT-2.EPO1Y/ cells expressed similar lev-
els of IL-17RA whether grown in EPO or IL-2 (Fig. 1E). How-
ever, HT-2.EPO5Y/ cells expressed a higher level of IL-17RA
when cultured in EPO compared with IL-2, consistent with the
microarray results. Moreover, IL-17RA expression was sup-
pressed when EPO5Y/ cells were co-cultured with EPO and
IL-2 together, suggesting that the PI3K pathway (in this case,
activated through the endogenous IL-2R) inhibits IL-17RA
expression (Fig. 1E).
IL-17RA Is Induced by IL-15 and IL-21 and Is Inhibited by
IL-2—In a published microarray screen of CD8 T cell genes,
the c cytokine IL-21 was reported to up-regulate IL-17RA
mRNA, which was the first suggestion that IL-17RA is subject
to immune regulation (25). Accordingly, we examined IL-17RA
regulation byc cytokines inHT-2 cells. Indeed, both IL-21 and
IL-15 up-regulated IL-17RA compared with IL-2 in a dose-de-
pendent manner (Fig. 2A and supplemental Fig. S1). Moreover,
IL-2 dominantly suppressed the effects of either IL-15 or IL-21,
at the level of both surface expression and mRNA (Fig. 2).
The disparity in signaling between IL-2 and IL-15 was unex-
pected, because these cytokines use identical signaling subunits
(2).However, a recent study suggested that IL-2 and IL-15 differ
in the ability to activate the PI3K pathway, at least with respect
to p70S6K activation (44). To determine the basis for signaling
differences between IL-2 and IL-15 in HT-2 cells, we examined
signaling events known to be activated by these cytokines. IL-2,
IL-15, and IL-21 all activated JAK1 phosphorylation and
STAT-5 nuclear import essentially equivalently (Fig. 3, A and
B). Therefore, differences between IL-2 and IL-15 are likely not
due to JAK or STAT activation.
The c-family cytokines have many redundant functions,
including proliferation and protection from apoptosis. How-
ever, prior studies using the EPO chimeric system indicate that
signaling through IL-4, IL-7, and IL-9 do not support prolifer-
ation in HT-2 cells, although all receptors effectively activate
their respective STAT complexes. In addition, IL-7 and IL-9
FIGURE 2. IL-17RA is inducedby IL-15 and IL-21 but not by IL-2. A, IL-2 dominantly suppresses IL-17RA surface expressionmediated by IL-15 and IL-21. HT-2
cells were treated for 24 h with the indicated cytokines, and IL-17RA surface expression was assessed by flow cytometry. Filled histograms, isotype control.
Average mean fluorescent intensity of IL-17RA expression relative to IL-2-treated cells was determined from five independent experiments (right panel). 2°,
secondary Ab alone. B, IL-2 dominantly suppresses IL-17RAmRNA expression mediated by IL-15 and IL-21. HT-2 cells were treated for 24 h with the indicated
cytokines, and IL-17RA mRNA levels were determined in triplicate by real-time RT-PCR. *, p 0.05 compared with IL-2-treated control.
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can delay apoptosis induced by IL-2 withdrawal (45–47). Here,
we found that IL-21 failed to promote proliferation or protect
cells from apoptosis (Fig. 3C), nor did IL-21 delay aG2 cell cycle
arrest (not shown). IL-15 has never been tested directly in these
cells, as the EPO chimeric system has long been assumed to
reflect both IL-2 and IL-15 signaling (7). Because we had
observed signaling differences between IL-2 and IL-15, we
assessed the ability of IL-15 to inhibit apoptosis and drive pro-
liferation. Indeed, both IL-2 and IL-15 protected HT-2 cells
from apoptosis caused by IL-2 starvation and triggered nearly
identical proliferative responses in short- and long-term cul-
ture (Fig. 3C). Therefore, IL-2 and IL-15 are indistinguishable
with respect to proliferative and survival responses in HT-2
cells, whereas IL-21 does not support proliferation.
In performing these studies, we
noted that HT-2 cells cultured in
IL-15 or IL-21 appeared smaller in
size than when cultured in IL-2.
This observation was confirmed
by forward scatter FACS profiles
(Fig. 3D). These data confirm that
IL-2 and IL-15 have indistinguish-
able mitogenic activities, whereas
IL-2 is a more potent growth fac-
tor (44). Notably, we made a simi-
lar observation with the chimeric
receptors; namely, HT-2.EPO
cells and HT-2.EPO1Y/ cells are
the same sizewhen grown in EPOor
IL-2, whereas HT-2.EPO5Y/
cells are smaller in EPO (Fig. 3D).
Therefore, despite an equivalent
ability to promote proliferation,
IL-2 induces cellular growth and
metabolism in a manner distinct
from IL-15 and IL-21. Moreover,
signaling by IL-15 appears to be
similar to HT-2.EPO5Y/, sug-
gesting that the PI3K pathway may
be differentially controlled by IL-2
and IL-15 in the same cell
background.
IL-2 and IL-15 Differentially
Induce the PI3K Pathway—Accord-
ingly, to assess activation of the
PI3K pathway by IL-2 and IL-15, the
p85 regulatory subunit of PI3K was
examined (Fig. 4A). To reduce acti-
vation of PI3K to baseline, cells were
starved without IL-2 for 2 h, and
then restimulated with IL-2, IL-15,
or IL-21 for various time points, and
phosphorylation of p85 was moni-
tored. The kinetics and magnitude
of p85 phosphorylationwere similar
at a 1-h time point (Fig. 4A). How-
ever, starting at 4 h and continuing
to 24 h, phosphorylation of p85 was
substantially reduced in IL-15-treated or IL-21-treated cells
compared with IL-2-treated cells (Fig. 4A). Therefore, IL-15
and IL-21 are unable to sustain PI3K activation over a time
frame that correlates with IL-17RA gene regulation. Although
many T cell lines have defects in the PI3K pathway (48), we
verified thatHT-2 cells express normal levels of both PTENand
SHIP and do not exhibit constitutive activation of Akt (Fig. 4B
and data not shown) (32).
To test the hypothesis that the PI3K pathway is responsible
for IL-2-mediated suppression of IL-17RA,HT-2 cellswere cul-
tured in IL-2 in the presence of PI3K inhibitors,Wortmannin or
LY294002. IL-17RA was up-regulated in the presence of both
these inhibitors, further demonstrating the ability of the PI3K
pathway to limit IL-17RA expression (Fig. 4C). In contrast, the
FIGURE 3. IL-2 and IL-15 differentially activate the PI3K pathway but not the JAK-STAT-5 pathway or
proliferation in HT-2 cells. A, IL-2, IL-15, and IL-21 activate JAK1 equivalently in HT-2 cells. HT-2 cells were
stimulated for 15 min with the indicated cytokines. Lysates were immunoprecipitated with -JAK1 Abs, sepa-
rated by SDS-PAGE, and immunoblottedwith-PTyr (4G10) Abs (top) or-JAK1 Abs (bottom). B, IL-2, IL-15 and
IL-21 activate STAT-5 equivalently in HT-2 cells. HT-2 cells were stimulated for 15 min with the indicated
cytokines.Nuclear extractswere subjected toEMSAwith a 32P-labeledSTAToligonucleotide (7) (whichbinds to
STAT-1, 5, 6 and to a lesser extent STAT-3). FP, free probe. Supershifting with -STAT-5 Abs was performed in
lanes 4, 6, and 8. Arrows indicate shifted and supershifted complexes. C, IL-2, IL-15, but not IL-21 drive prolifer-
ation and inhibit apoptosis in HT-2 cells. HT-2 cells were cultured for 24, 48, or 72 h in the indicated cytokines
and concentrations. Proliferation was assessed by [3H]thymidine incorporation in triplicate S.D., *, p 0.05.
Apoptosis was determined by FACS staining with propidium iodide and GFP-Annexin V, and apoptotic cells
were defined as PI-negative/GFP-Annexin V-positive, as described in Ref. 32, 60. Data are representative of
three experiments.D, signaling from PI3K via IL-2 and Y338 promotes increased cell size. HT-2 cells (top panel)
or HT-2 cells expressing the indicated EPO-IL-2R chimeras (bottom 3 panels) were cultured in the indicated
cytokines for 24 h, and cell size was assessed by forward scatter analysis by flow cytometry.
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inhibitor rapamycin, which blocks
mTOR, p70S6K activation, and IL-2-
induced proliferation (16), did not
relieve IL-2-induced suppression
of IL-17RA, although rapamycin
did effectively inhibit phosphoryla-
tion of p70S6K. Activation of p70S6K
was much stronger in IL-2-induced
cells than in IL-15-induced HT-2
cells (Fig. 4D). However, because
rapamycin had no effect on IL-15-
mediated induction of IL-17RA, it is
unlikely that this arm of the PI3K
pathway is involved in the differen-
tial regulation of IL-17RA by these
cytokines. Together, these data
indicate that the downstream target
of PI3K with respect to IL-17RA
regulation is apparently not p70S6K.
To determine if Akt, also a PI3K
target, is involved in IL-17RA regu-
lation, HT-2 cells were stably trans-
fected with a myristoylated form
Akt that is constitutively active (34).
Clonal lines expressing Myr-Akt
showed constitutive Akt phospho-
rylation and prolonged survival fol-
lowing IL-2 withdrawal (Fig. 5, A
and B), confirming the functionality
of Myr-Akt. As shown in Fig. 4A,
depriving HT-2 cells of IL-2 caused
a reduction in PI3K activation. This
was accompanied by a concomitant
up-regulation in IL-17RA expres-
sion after 22 h of IL-2 starvation
(Fig. 5C and data not shown). How-
ever, in Myr-Akt cells, there was
almost no enhancement of IL-17RA
following IL-2 withdrawal, consist-
ent with a dominant suppressive
effect of the PI3K/Akt signaling
pathway on IL-17RA expression
(Fig. 5C).
Differential signaling between
IL-2 and IL-15 has been reported in
primary CD8 T cells previously
with respect to cell size, growth, and
gene expression (44). To determine
whether c cytokines differentially
regulate IL-17RA in vivo, we stimu-
lated CD8T cells purified bymag-
netic beads with IL-2, IL-15, and
IL-21 and stained for IL-17RA (Fig.
6). As shown, IL-21 induced
IL-17RA to high levels, which is
consistent with a previous report
(25). However, when cultured with
the PI3K inhibitor LY294002, IL-15
FIGURE 4. The PI3K pathway inhibits IL-17RA expression. A, sustained phosphorylation of p85 induced by
IL-2 but not IL-15 or IL-21. HT-2 cells were cultured in IL-2, IL-15, or IL-21 for the indicated time points, and
phosphorylationof thep85/was assessedas in Fig. 1.B, HT-2 cells express PTENandSHIP. Lysates fromHT-2,
Jurkat T cells or the A20 B cell line were immunoblotted with Abs to PTEN or IKK (top panels) or immunopre-
cipitatedwith-SHIP Abs andprobed for SHIP (bottompanel).C, PI3K inhibitors up-regulate IL-17RA. HT-2 cells
were incubated in IL-2 LY294002 or Wortmannin for 20 h. IL-17RA expression was assessed by flow cytom-
etry. D, rapamycin inhibits p70S6K but not IL-15-induced IL-17RA expression. HT-2 cells were incubated with
IL-2 or IL-15 Rapamycin for 20 h. IL-17RA (top) or p70S6K (bottom) were assessed by flow cytometry.
FIGURE 5. A constitutively active form of Akt promotes IL-17RA expression. A, HT-2 cells stably express
Myr-Akt. Lysates from 3 HT-2 subcloned stably transfected with Myr-Akt were immunoblotted with -pAkt
(Ser-473). B, Myr-Akt delays apoptosis induced by cytokine withdrawal. HT-2 cells expressing Myr-Akt (clones
A26 and A39) were incubated with or without IL-2 for the indicated time points, and cell survival (PI-negative)
or apoptosis (GFP-Annexin V-positive) cells were assessed by flow cytometry. C, expression of a constitutively
active formof Akt prevents up-regulation of IL-17RA inducedby cytokinewithdrawal. HT-2 or HT-2.MyrAktA39
cells were deprived of IL-2 for the indicated times, and IL-17RA expression was assessed by flow cytometry.
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up-regulated IL-17RA significantly more strongly than IL-2.
Although these data do not precisely mirror findings in HT-2
cells, they nonetheless indicate differential use of the PI3K
pathway by these cytokines in terms of IL-17RA expression. It
should be noted that the lineage of HT-2 cells is unclear, as they
express both CD4 and CD8.3 Because purified CD8 T cells
probably contain multiple distinct subsets of cells with poten-
tially different capacities for responsiveness to cytokines, the
finding that IL-2 and IL-15 can regulate distinct responses in a
single cell line provides compelling evidence that these cyto-
kines are capable of mediating distinct biochemical signals.
IL-17 Mediates Down-regulation of IL-17RA—IL-17RA is
expressed ubiquitously, but its functions have been determined
primarily in nonimmune cell types such as mesenchymal and
epithelial cells (31). T and B cell lines express high levels of
IL-17RA (Ref. 30),3 but the functional significance of this
expression is unknown. BecauseHT-2 cells express a high base-
line level of IL-17RA, we treated cells with IL-17 and evaluated
the consequences to gene expression. Surprisingly, there was
no expression of known IL-17 target genes (35) in either HT-2
cells or primary CD8 T lymphocytes, including IL-6, LIX/
CXCL5, Gro/KC/CXCL1, or 24p3 (Fig. 7, A and B and data
not shown) following IL-17 stimulation. Therefore, T cells
appear refractory to IL-17 signaling, at least in terms of known
gene expression. This is at least partly due to a lack of detectable
IL-17RC mRNA expression in this cell line by RT-PCR (data
not shown).
DISCUSSION
A major advance in understanding T cell differentiation
occurred with the recognition of a distinct population of
IL-17-secreting T cells, “Th17.” Th17 cells are now recog-
nized to be the major drivers of autoimmunity (49). How-
ever, the functions of IL-17 and other Th17-derived cyto-
kines are still being defined. The IL-17 receptor subunit
IL-17RA is highly expressed on non-immune cells such as
epithelial cells and fibroblasts, where it acts similarly to
innate immune cytokines and Toll-like receptors to amplify
inflammation via expression of IL-6, chemokines, and other
pro-inflammatory effectors (35). Studies of IL-17RA-defi-
cient mice have identified defects in neutrophil development
and recruitment, leading to increased susceptibility to infec-
tious disease but resistance to chronic, autoimmune condi-
tions (50, 51). However, IL-17RA is expressed on lympho-
cytes as well, where its function and regulation are poorly
defined. A prior microarray study identified IL-21 as an
inducer of IL-17RA in CD8 T cells (25). Here, we confirm
and extend that finding using chimeric IL-2 receptor
mutants defective in PI3K activation. We further show that
IL-2, IL-15, and IL-21 differentially regulate IL-17RA
through the PI3K-Akt pathway.
Detailed studies of Th17 differentiation have implicated
the c cytokine family. Th17 differentiation is driven by
TGF in combination with IL-6, and the STAT-3 transcrip-
tion factor is essential for this event. IL-23 serves as a prolif-
eration signal to specifically expand Th17 cells, which exclu-
sively express the IL-23R (49). Recently, it was shown that
IL-21, which also activates both STAT-3, drives Th17 differ-
entiation downstream of IL-6 and is necessary for optimal
Th17 function in vivo (26–28). Conversely, Th1 and Th2
cytokines (IFN and IL-4, respectively) inhibit Th17 devel-
opment (52, 53). IL-2 has also been shown to inhibit Th17
differentiation, favoring expansion of the T regulatory cell
(Treg) lineage. This is mediated by STAT-5 (23). Although
IL-15 has not been implicated in Th17 differentiation, there
is evidence that IL-15 can enhance IL-17 expression (29).
Therefore, our finding that IL-2 limits IL-17RA expression
whereas IL-15 and IL-21 promote it (Fig. 2A) is consistent
with the overall model of Th17 differentiation.
The function of IL-17 in T cells is unknown. Lymphocytes,
both primary cells and lymphocyte cell lines, express
IL-17RA (Fig. 1 and data not shown). However, canonical
IL-17 target genes such as IL-6 and chemokines are not
induced, either in HT-2 cells or primary T cells (Fig. 7, A and
B). In HT-2 cells this appears to be due to a lack of IL-17RC
expression,3 an IL-17R superfamily member that was
recently shown to be an essential component of the IL-17R
complex (54). However, IL-17RC mRNA is present in pri-
mary CD8 populations,3 though we do not know whether
this subunit is expressed at the surface. Nor do we find that
IL-17 can promote proliferation, survival, or apoptosis in T
cells.3 It is possible that IL-17 target genes are completely
non-overlapping in T cells compared with fibroblasts and
epithelial cells. Alternatively, IL-17RA may bind to another,
unknown ligand. Further experimentation will be necessary
to determine the function of IL-17RA in T cells.
There is increasing evidence that IL-2 and IL-15 exhibit
differential effects on target cells, despite using identical sig-
naling subunits in their respective receptor complexes (44,
55, 56). However, most studies to date have been performed
in primary lymphocytes, where subpopulations may express
different levels of IL-15R and IL-2R and hence respond
differentially to the same cytokines. One microarray study
showed highly similar gene expression induced by IL-2 and3 M. J. Lindemann, unpublished observations.
FIGURE 6. Regulation of IL-17RA in primary CD8 T cells. Splenic CD8 T
cells were purified by magnetic beads and stimulated for 6 h with the indi-
cated cytokineswithDMSO (top) or LY294002 (bottom). IL-17RAwas assessed
by flow cytometry.
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IL-15, suggesting few or no signaling differences between
these cytokines (57).
Here, we examined c cytokine signaling in a controlled
and uniform system with the IL-2-dependent T cell line,
HT-2. We show for the first time that an IL-2Rmutant that
cannot activate the PI3K pathway inhibits expression of
many immunomodulatory genes, including IL-17RA (Fig.
1D, supplemental Tables S1 and S2). Surprisingly, despite
the use of identical signaling subunits, IL-15 promotes
IL-17RA expression and fails to maintain long-term activa-
tion of the PI3K-p85 pathway (Fig. 3A). Moreover, HT-2
cells grown in IL-15 or HT-2.EPO5Y/ cells grown in EPO
were reproducibly smaller than cells cultured in IL-2 or
HT-2.EPO and HT-2EPO1Y/ cells grown in EPO (Fig.
3D); thus, cell size correlates with activation of the PI3K
pathway.
The reason that IL-15 does not sustain PI3K is not certain.
However, unlike IL-2, IL-15 can be presented in a “trans-
signaling” mode, wherein IL-15R on a neighboring cell
binds IL-15 and induces signaling on a target cell lacking
IL-15R (58). It is believed that this mode of presentation
permits IL-15 to have a longer stimulatory half-life com-
pared with soluble IL-15 (59), which may influence its sig-
naling properties (e.g. the duration in which PI3K is acti-
vated). We also observed slightly more enhanced JAK1
activation by IL-2, which could possibly contribute to a more
potent downstream signal (Fig. 3A).
Although our studies in primary T cells do not precisely
mirror effects in HT-2 cells, we nonetheless observe differ-
ences in signaling between IL-2 and IL-15, which are
revealed most strongly when the
PI3K pathway is blocked (Fig. 6).
Clearly IL-21 is a more potent
inducer of IL-17RA in primary
CD8 T cells, which may be bio-
logically relevant in light of the
fact that IL-21 is an autocrine
inducer of the Th17 pathway
(26–28).
The present studies suggest that
IL-2-induced PI3K activation limits
IL-17RA gene expression, but HT-2
cells still maintain a fairly high
baseline level of IL-17RA even in
the presence of IL-2. Thus, there are
likely to be separate regulatory ele-
ments that govern baseline versus
inducible levels of the IL-17RA
gene. The promoter for IL-17RA is
uncharacterized, and few clues can
be gleaned from phylogenetic align-
ments of its proximal promoter
region.3 However, it is clear that
IL-17RA is subject tomodulation by
inflammatory factors such as c
cytokines including IL-21, IL-15,
and IL-4 (25, 52, 53). Therefore,
future studies will be directed at
understanding this process in molecular detail.
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